The Japanese Ministry of Health, Labor and Welfare (MHLW) has granted marketing approval of Boston Scientific Corporation (NYSE: BSX)’s TAXUS® Express2™ paclitaxel-eluting coronary stent system.
According to Jim Tobin, President and Chief Executive Officer of Boston Scientific:
"The approval of the TAXUS® Express2™ stent is an important event for the treatment of cardiovascular disease in Japan. We are pleased to provide Japanese physicians with this proven technology, which will help improve the quality of life for so many patients."
Boston Scientific will be launching the product into the Japanese market soon.
Read the full report.
Comment Preview